BACKGROUND: In Sub-Saharan Africa, prevalence estimates of hepatitis C virus (HCV) vary widely. OBJECTIVES: To assess the prevalence of HCV infection among HIV-infected, pregnant women screened for a large clinical trial in Lilongwe, Malawi. STUDY DESIGN: Plasma from 2041 HIV-infected, pregnant women was screened for anti-HCV IgG using a chemiluminiscent immunometric assay (CIA). Specimens with a signal-cut-off ratio≥1.00 were considered reactive and those with S/Co ratio<1.00 non-reactive. All CIA-reactive specimens were tested by a recombinant immunoblot assay (RIBA) for anti-HCV and by PCR for HCV RNA. RESULTS: Of 2041 specimens, 110 (5.3%, 95% CI: 4.5-6.5%) were CIA reactive. Of the 109 CIA reactive specimens available for RIBA testing, 2 (1.8%) were positive, 28 (25.7%) were indeterminate, and 79 (72.5%) were negative. All CIA-reactive specimens were HCV RNA negative (n=110). The estimated HCV prevalence based on the screening assay alone was 5.3%; based on supplemental RIBA testing, the status of HCV infection remained indeterminate in 1.4% (28/2040, 95% CI: 0.1-2.0) and the prevalence of confirmed HCV infections was 0.1% (2/2040, 95% CI: 0-0.4%). CONCLUSIONS: HCV seroprevalence among HIV-infected, pregnant women in Malawi confirmed by supplemental RIBA HCV 3.0 is low (0.1%); CIA showed a high false-reactivity rate in this population. Published by Elsevier B.V.
BACKGROUND: In Sub-Saharan Africa, prevalence estimates of hepatitis C virus (HCV) vary widely. OBJECTIVES: To assess the prevalence of HCV infection among HIV-infected, pregnant women screened for a large clinical trial in Lilongwe, Malawi. STUDY DESIGN: Plasma from 2041 HIV-infected, pregnant women was screened for anti-HCV IgG using a chemiluminiscent immunometric assay (CIA). Specimens with a signal-cut-off ratio≥1.00 were considered reactive and those with S/Co ratio<1.00 non-reactive. All CIA-reactive specimens were tested by a recombinant immunoblot assay (RIBA) for anti-HCV and by PCR for HCV RNA. RESULTS: Of 2041 specimens, 110 (5.3%, 95% CI: 4.5-6.5%) were CIA reactive. Of the 109 CIA reactive specimens available for RIBA testing, 2 (1.8%) were positive, 28 (25.7%) were indeterminate, and 79 (72.5%) were negative. All CIA-reactive specimens were HCV RNA negative (n=110). The estimated HCV prevalence based on the screening assay alone was 5.3%; based on supplemental RIBA testing, the status of HCV infection remained indeterminate in 1.4% (28/2040, 95% CI: 0.1-2.0) and the prevalence of confirmed HCV infections was 0.1% (2/2040, 95% CI: 0-0.4%). CONCLUSIONS:HCV seroprevalence among HIV-infected, pregnant women in Malawi confirmed by supplemental RIBA HCV 3.0 is low (0.1%); CIA showed a high false-reactivity rate in this population. Published by Elsevier B.V.
Authors: E Moore; M B J Beadsworth; M Chaponda; B Mhango; B Faragher; J Njala; H W C Hofland; J Davies; I J Hart; N J Beeching; E E Zijlstra; J J van Oosterhout Journal: J Infect Date: 2010-05-12 Impact factor: 6.072
Authors: W Hladik; P Kataaha; J Mermin; M Purdy; G Otekat; E Lackritz; M J Alter; R Downing Journal: Trop Med Int Health Date: 2006-06 Impact factor: 2.622
Authors: François Rouet; Marie-Laure Chaix; André Inwoley; Philippe Msellati; Ida Viho; Patrice Combe; Valériane Leroy; François Dabis; Christine Rouzioux Journal: J Med Virol Date: 2004-09 Impact factor: 2.327
Authors: Chloe L Thio; Eric C Seaberg; Richard Skolasky; John Phair; Barbara Visscher; Alvaro Muñoz; David L Thomas Journal: Lancet Date: 2002-12-14 Impact factor: 79.321
Authors: Siobhan Sutcliffe; Taha E Taha; Newton I Kumwenda; Ellen Taylor; George N Liomba Journal: J Acquir Immune Defic Syndr Date: 2002-09-01 Impact factor: 3.731
Authors: Caroline E Mullis; Oliver Laeyendecker; Steven J Reynolds; Ponsiano Ocama; Jeffrey Quinn; Iga Boaz; Ronald H Gray; Gregory D Kirk; David L Thomas; Thomas C Quinn; Lara Stabinski Journal: Clin Infect Dis Date: 2013-09-18 Impact factor: 9.079
Authors: Kathleen N Ly; Andrea A Kim; Jan Drobeniuc; Maja Kodani; Joel M Montgomery; Barry S Fields; Eyasu H Teshale Journal: Am J Trop Med Hyg Date: 2018-04-19 Impact factor: 2.345
Authors: James M Fox; Robert Newton; Marija Bedaj; Ada Keding; Elizabeth Molyneux; Lucy M Carpenter; Fabiola Martin; Nora Mutalima Journal: Trop Med Int Health Date: 2015-02-06 Impact factor: 2.622
Authors: Gilles Wandeler; Lloyd Mulenga; Michael Hobbins; Candido Joao; Edford Sinkala; Jonas Hector; Musa Aly; Benjamin H Chi; Matthias Egger; Michael J Vinikoor Journal: Open Forum Infect Dis Date: 2016-03-02 Impact factor: 3.835